Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies

Human papillomavirus type 58 L1 virus-like particles purified by two-step chromatography elicit high levels of long-lasting neutralizing antibodies
复制标题

通过两步色谱纯化的人乳头瘤病毒 58 L1 型病毒样颗粒可引发高水平的持久中和抗体

DOI:
10.1007/s00705-012-1465-x
复制
发表时间:
2012-09
影响因子:
2.7
通讯作者:
Xuemei Xu
Xuemei Xu
中科院分区:
医学4区
文献类型:
--
作者:
Xixiu Xie;Yanchun Liu;Ting Zhang;Yanying Xu;Qifeng Bao;Xue Chen;Hongyang Liu;Xuemei Xu

文献摘要

参考文献

被引文献

相似文献

人乳头瘤病毒(HPV)58型是一种高危型HPV,常在宫颈癌中检出,特别是在东亚。目前还没有针对HPV 58感染的市售疫苗。高水平的持久中和抗体对于长期预防HPV感染至关重要。在这里,我们已经开发了一种两步层析策略,并纯化了高纯度的HPV L1蛋白,其形成比CsCl超离心纯化的更均匀和均匀的VLP。用HPV 58 L1 VLP单独或与HPV 16和HPV 18 L1 VLP共同施用的低剂量免疫足以在小鼠中诱导高水平的持久中和抗体。我们的研究结果表明,高免疫原性HPV 58 L1 VLP是一个很好的候选人,用于开发有效的疫苗对HPV 58感染。
Human papillomavirus (HPV) type 58 is a high-risk type of HPV frequently detected in cervical cancers, especially in Eastern Asia. There are still no commercially available vaccines against HPV 58 infection. High levels of long-lasting neutralizing antibodies are crucial for long-term protection against HPV infection. Here, we have developed a two-step chromatography strategy and have purified highly pure HPV L1 proteins, which form more homogenous and uniform VLPs than those purified by CsCl ultracentrifugation. Low-dosage immunization with HPV 58 L1 VLPs alone or co-administrated with HPV 16 and HPV 18 L1 VLPs is sufficient to induce high levels of long-lasting neutralizing antibodies in mice. Our results suggest that the highly immunogenic HPV 58 L1 VLPs are a good candidate for use in developing effective vaccines against HPV 58 infection.
DOI: 10.1016/j.vaccine.2010.02.057
发表时间: 2010-04
期刊: Vaccine
影响因子: 5.5
作者:
Ting Zhang;Yu-fei Xu;L. Qiao;Youchun Wang;Xueling Wu;Dongsheng Fan;Qinglin Peng;Xue-mei Xu
通讯作者: Ting Zhang;Yu-fei Xu;L. Qiao;Youchun Wang;Xueling Wu;Dongsheng Fan;Qinglin Peng;Xue-mei Xu
DOI: 10.1016/j.virol.2003.12.027
发表时间: 2004-04-10
期刊: VIROLOGY
影响因子: 3.7
作者:
Pastrana, DV;Buck, CB;Schiller, JT
通讯作者: Schiller, JT
DOI: 10.1038/sj.gt.3302611
发表时间: 2005-10-01
期刊: GENE THERAPY
影响因子: 5.1
作者:
Burova, E;Loffe, E
通讯作者: Loffe, E
DOI: 10.1042/ba20000001
发表时间: 2000-08-01
影响因子: 2.8
作者:
Fang, NX;Frazer, IH;Fernando, GJP
通讯作者: Fernando, GJP
DOI: 10.1099/0022-1317-75-9-2445
发表时间: 1994-09
期刊: The Journal of general virology
影响因子: --
作者:
R. Rose;W. Bonnez;Caroline Da Rin;D. McCance;R. Reichman
通讯作者: R. Rose;W. Bonnez;Caroline Da Rin;D. McCance;R. Reichman